TY - JOUR
T1 - Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
AU - Bisceglia, I.
AU - Canale, M. L.
AU - Silvestris, N.
AU - Gallucci, G.
AU - Camerini, A.
AU - Inno, A.
AU - Camilli, M.
AU - Turazza, F. M.
AU - Russo, G.
AU - Paccone, A.
AU - Mistrulli, R.
AU - De, Luca L.
AU - Di, Fusco S. A.
AU - Tarantini, L.
AU - Luca, F.
AU - Oliva, Stefano Claudio
AU - Moreo, A.
AU - Maurea, N.
AU - Quagliariello, V.
AU - Ricciardi, G. R.
AU - Lestuzzi, C.
AU - Fiscella, D.
AU - Parrini, I.
AU - Racanelli, V.
AU - Russo, A.
AU - Incorvaia, L.
AU - Calabro, F.
AU - Curigliano, G.
AU - Cinieri, S.
AU - Gulizia, M. M.
AU - Gabrielli, D.
AU - Oliva, F.
AU - Colivicchi, F.
PY - 2023
Y1 - 2023
N2 - In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of life. With improvements in early diagnosis and treatment, the number of cancer survivors (CS) has grown considerably and includes: (1) Patients cured and free from cancer who may be at risk of late-onset cancer therapy-related cardiovascular toxicity (CTR-CVT); (2) Patients with long-term control of not-curable cancers in whom CTR-CVT may need to be addressed. This paper highlights the importance of the cancer care continuum, of a patient-centered approach and of a prevention-oriented policy. The ultimate goal is a personalized care of CS, achievable only through a multidisciplinary-guided survivorship care plan, one that replaces the fragmented management of current healthcare systems. Collaboration between oncologists and cardiologists is the pillar of a framework in which primary care providers and other specialists must be engaged and in which familial, social and environmental factors are also taken into account.
AB - In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of life. With improvements in early diagnosis and treatment, the number of cancer survivors (CS) has grown considerably and includes: (1) Patients cured and free from cancer who may be at risk of late-onset cancer therapy-related cardiovascular toxicity (CTR-CVT); (2) Patients with long-term control of not-curable cancers in whom CTR-CVT may need to be addressed. This paper highlights the importance of the cancer care continuum, of a patient-centered approach and of a prevention-oriented policy. The ultimate goal is a personalized care of CS, achievable only through a multidisciplinary-guided survivorship care plan, one that replaces the fragmented management of current healthcare systems. Collaboration between oncologists and cardiologists is the pillar of a framework in which primary care providers and other specialists must be engaged and in which familial, social and environmental factors are also taken into account.
KW - cancer survivors (CSs)
KW - cancer therapy-related cardiovascular toxicities (CTR-CVT)
KW - cardiovascular disease (CVD)
KW - cardiovascular risk factors (CVRF)
KW - reverse cardio-oncology
KW - survivorship care
KW - cancer survivors (CSs)
KW - cancer therapy-related cardiovascular toxicities (CTR-CVT)
KW - cardiovascular disease (CVD)
KW - cardiovascular risk factors (CVRF)
KW - reverse cardio-oncology
KW - survivorship care
UR - https://publicatt.unicatt.it/handle/10807/323198
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85173595814&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85173595814&origin=inward
U2 - 10.3389/fcvm.2023.1223660
DO - 10.3389/fcvm.2023.1223660
M3 - Article
SN - 2297-055X
VL - 10
SP - N/A-N/A
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
IS - Sep
ER -